
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer 19 April 2024
Oslo, Norway, April 19, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical... Read more

Oslo, Norway, April 19, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical... Read more

Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ:... Read more

Gubra announces the selection of a development candidate and unveils urocortin-2 (UCN2) as a novel anti-obesity... Read more

Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies... Read more

ELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA)... Read more

On 21 March 2024, the company released the great news about the peer-reviewed publication in the journal... Read more
The EU Commision has published the initiative: ”Building the future with nature: Boosting Biotechnology... Read more

First Cannabidiol drug formulation from partnership to enter clinical studies in 2024 February 15, 2024... Read more

Coming Phase I/IIa basket trial planned to include five select cancer indications Study will apply Curasight’s... Read more